» Articles » PMID: 12885755

Disruption of Leptin Signaling Contributes to Cardiac Hypertrophy Independently of Body Weight in Mice

Overview
Journal Circulation
Date 2003 Jul 30
PMID 12885755
Citations 139
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Whether left ventricular hypertrophy (LVH) in obesity results from increased hemodynamic load or altered neurohormonal signaling remains controversial. Dysregulation of leptin, a neurohormone essential to energy homeostasis, is implicated in the pathogenesis of obesity. Because leptin has cardiovascular bioactivity, we hypothesized that disruption of leptin signaling mediates the development of obesity-associated LVH.

Methods And Results: We measured left ventricular (LV) wall thickness and LV mass with echocardiography in mice lacking leptin (ob/ob, n=15) or functional receptor (db/db, n=10) and controls at 2, 4, and 6 months of age. None of the mice had LVH at 2 months. Progressive obesity developed in ob/ob and db/db mice. At 6 months, LVH occurred in ob/ob and db/db compared with controls. We observed corresponding myocyte hypertrophy by light microscopy. To separate the direct contribution of leptin deficiency from mechanical effects of obesity, we induced weight loss in 6- to 8-month-old ob/ob mice either by leptin infusion or caloric restriction. Mice in both groups lost similar weight compared with placebo-treated controls. Leptin infusion completely reversed the increase in wall thickness with partial resolution of myocyte hypertrophy, whereas calorie-restricted mice had no decrease in wall thickness and a lesser change in myocyte size.

Conclusions: Together these data show that the effect of leptin on LV remodeling is not attributable to weight loss alone, indicating that leptin has antihypertrophic effects on the heart, either directly or through a leptin-regulated neurohumoral pathway. Disruption of leptin signaling may represent a novel mechanism in LVH and related cardiovascular disorders.

Citing Articles

An integrated view of the pathophysiological crosstalk between adipose tissue, bone and cardiovascular system in men and women.

Klinaku F, Comi L, Giglione C, Magni P J Endocrinol Invest. 2024; .

PMID: 39692990 DOI: 10.1007/s40618-024-02516-x.


Targeting the Brain Leptin-Melanocortin Pathway to Treat Heart Failure.

Omoto A, do Carmo J, Mouton A, Wang Z, Li X, Spitz R Curr Hypertens Rep. 2024; 27(1):2.

PMID: 39612121 PMC: 11607000. DOI: 10.1007/s11906-024-01318-z.


Lifestyle interventions in cardiometabolic HFpEF: dietary and exercise modalities.

Vacca A, Wang R, Nambiar N, Capone F, Farrelly C, Mostafa A Heart Fail Rev. 2024; .

PMID: 39283525 DOI: 10.1007/s10741-024-10439-1.


Central Actions of Leptin Induce an Atrophic Pattern and Improves Heart Function in Lean Normoleptinemic Rats via PPARβ/δ Activation.

Rubio B, Pintado C, Mazuecos L, Benito M, Andres A, Gallardo N Biomolecules. 2024; 14(8).

PMID: 39199415 PMC: 11352611. DOI: 10.3390/biom14081028.


Association of attenuated leptin signaling pathways with impaired cardiac function under prolonged high-altitude hypoxia.

Wang J, Liu S, Sun L, Kong Z, Chai J, Wen J Sci Rep. 2024; 14(1):10206.

PMID: 38702334 PMC: 11068766. DOI: 10.1038/s41598-024-59559-6.